MentionFox
Home › funding signals › Inmedix, Inc.
Form D · on the record

Inmedix — $4.01M Form D filing, October 2026

Inmedix, Inc. filed an amended Form D with the Securities and Exchange Commission on 2026-10-22.

Inmedix, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on October 22, 2026. The filing reports $4.01M sold. Its industry group is Biotechnology. It names Andrew Holman, M.D. (Executive Officer, Director), Steven Daly, M.S., M.B.A. (Director), Bernie Tobin (Director) (SEC Form D/A, October 22, 2026).

5 more Biotechnology raises in Washington within 90 days ↓

Sell to companies like Inmedix, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

Run the free check on Inmedix, Inc. →

Inmedix, Inc.

New Form D on file · 2026-10-22 · the record

$4.01M
raise on the record
D/A
filing
34
investors in
WASHINGTON
based
Open the record →

What the record says

FilingForm D/A (amended)
Filed2026-10-22
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
BasedNORMANDY PARK, WASHINGTON
CIK1851853
Accession0001851853-26-000001

Pitching, partnering or investing alongside them? See who really runs and owns Inmedix, Inc.

Watch Inmedix, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind Inmedix, Inc., from the filings we hold.

More raises like this

Biotechnology raises by companies based in Washington, filed within 90 days of this one, largest first.

What do you want to do with Inmedix, Inc.?

Get the full cited report on Inmedix, Inc.

What the filing shows about Inmedix, Inc.

  • The filing reports $120K of the proceeds going to the company's own executives, directors or promoters.
  • 34 investors had already put money in when it filed.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Inmedix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

What the filing says

  • Offered: $5,000,000. Sold: $4,009,945. Left to sell: $990,055. (filing)
  • Investors: 34 had already invested. (filing)
  • Date of first sale: September 24, 2025. (filing)
  • Types of securities: Debt. (filing)
  • Item 16, payments to executive officers, directors or promoters: $120,000 of the proceeds is used or proposed to be used for such payments. The filing gives no explanation. (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Inmedix, Inc. See pricing

Filing history · 4 filings on this registrant
Form D · 2023-04-25 · $25KForm D · 2024-11-01 · $720KForm D · 2025-10-06 · $160KForm D/A, amended · 2026-10-22 · $4.01M · this page 2023-04-25 2026-10-22

A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.

Biotechnology · by week
This raise, $4.01M, filed week of Oct 19

Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $4.01M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Inmedix, Inc.?

What the filing shows about Inmedix, Inc.

  • The filing reports $120K of the proceeds going to the company's own executives, directors or promoters.
  • 34 investors had already put money in when it filed.
  • The filing names 6 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Inmedix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Inmedix, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Inmedix, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for Inmedix, Inc.. With no account yet, you sign up free and land on the result.

Share this page

Just raised? Share it.

Inmedix, Inc.: Raised $4.01M, Form D filed 2026-10-22

Cite this page

Permanent URL: https://mentionfox.com/funding/inmedix-inc-form-d-000001
Last updated 2026-10-25
Primary record: SEC filing 1 · SEC filing 2
Inmedix raised $4.01M — SEC Form D filing, October 2026. MentionFox, 2026-10-25. https://mentionfox.com/funding/inmedix-inc-form-d-000001